FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
1.360
-0.070 (-4.90%)
Apr 28, 2026, 4:00 PM EDT - Market closed

FibroBiologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Selling, General & Admin
9.249.236.523.321.06
Upgrade
Research & Development
7.414.52.371.150.52
Upgrade
Operating Expenses
16.6513.748.894.471.58
Upgrade
Operating Income
-16.65-13.74-8.89-4.47-1.58
Upgrade
Interest Expense
-0.2-0.02-0.15-0.65-0
Upgrade
Interest & Investment Income
0.250.25---
Upgrade
Other Non Operating Income (Expenses)
-2.042.35-7.45--
Upgrade
Pretax Income
-18.65-11.16-16.49-5.12-1.58
Upgrade
Net Income
-18.65-11.16-16.49-5.12-1.58
Upgrade
Preferred Dividends & Other Adjustments
--2.57--
Upgrade
Net Income to Common
-18.65-11.16-19.06-5.12-1.58
Upgrade
Shares Outstanding (Basic)
22110
Upgrade
Shares Outstanding (Diluted)
22110
Upgrade
Shares Change (YoY)
35.85%16.45%-222.64%-
Upgrade
EPS (Basic)
-8.35-6.79-13.50-3.63-3.62
Upgrade
EPS (Diluted)
-8.35-6.79-13.50-3.63-3.62
Upgrade
Free Cash Flow
-16.66-12.09-6.9-4.07-1.41
Upgrade
Free Cash Flow Per Share
-7.46-7.35-4.88-2.88-3.22
Upgrade
EBITDA
-16.41-13.58-8.84--
Upgrade
D&A For EBITDA
0.240.160.05--
Upgrade
EBIT
-16.65-13.74-8.89-4.47-1.58
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.